Drug intelligence / Profile preview

CTH-700 series

Development stage: Preclinical
Lead developer: Cartherics
Modality: Gene Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Intraperitoneal

Overview

CTH-700 series is a preclinical-stage cell therapy platform developed by Cartherics for the treatment of endometriosis. The platform utilizes induced pluripotent stem cell (iPSC)-derived macrophages (iMacs) that are engineered with chimeric antigen receptors (CARs) and incorporate specific gene knockouts to enhance their therapeutic function. This approach is designed to overcome the immunosuppressive environment of endometriotic lesions and facilitate their clearance. By leveraging an iPSC-derived off-the-shelf model, the CTH-700 series aims to provide a scalable, standardized treatment for patients with endometriosis.

Beyond the preview

Go deeper on CTH-700 series.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-700 series.

Explore the full profile